Stephen Swisher
Overview
Explore the profile of Stephen Swisher including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
60
Citations
1999
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Schwalk A, Ost D, Saltijeral S, De La Garza H, Casal R, Jimenez C, et al.
Chest
. 2020 Nov;
159(3):1256-1264.
PMID: 33217413
Background: The main goal of management in patients with non-small cell lung cancer (NSCLC) and malignant pleural effusion (MPE) is palliation. Patients with MPE and actionable mutations, because their disease...
22.
Lee W, Reuben A, Hu X, McGranahan N, Chen R, Jalali A, et al.
Genome Biol
. 2020 Nov;
21(1):271.
PMID: 33148332
Background: Metastasis is the primary cause of cancer mortality accounting for 90% of cancer deaths. Our understanding of the molecular mechanisms driving metastasis is rudimentary. Results: We perform whole exome...
23.
Kris M, Faivre-Finn C, Kordbacheh T, Chaft J, Luo J, Tsao A, et al.
Am Soc Clin Oncol Educ Book
. 2020 Apr;
40:1-12.
PMID: 32298162
The PACIFIC trial of durvalumab administered for 1 year to patients with stage III lung cancers has set a new standard of care. PACIFIC established the role of immune checkpoint...
24.
Rice D, Rodriguez-Restrepo A, Mena G, Cata J, Thall P, Milton D, et al.
Ann Surg
. 2020 Apr;
274(6):1099-1106.
PMID: 32229762
Objective: The aim of this study was to assess the effect of an enhanced recovery after surgery (ERAS) pathway on pain and opioid use following lung resection. Summary Background Data:...
25.
Rajaram R, Correa A, Xu T, Nguyen Q, Antonoff M, Rice D, et al.
Clin Lung Cancer
. 2020 Feb;
21(4):e294-e301.
PMID: 32089476
Introduction: The standard of care for stage IIIA (N2) non-small-cell lung cancer (NSCLC) includes concurrent definitive chemoradiation (dCRT) followed by durvalumab, thus challenging the role of surgery in resectable patients....
26.
Reuben A, Zhang J, Chiou S, Gittelman R, Li J, Lee W, et al.
Nat Commun
. 2020 Feb;
11(1):603.
PMID: 32001676
Immunotherapy targeting T cells is increasingly utilized to treat solid tumors including non-small cell lung cancer (NSCLC). This requires a better understanding of the T cells in the lungs of...
27.
Simon G, DiNardo C, Takahashi K, Cascone T, Powers C, Stevens R, et al.
Oncologist
. 2018 Nov;
24(6):772-782.
PMID: 30446581
Background: Rapid advances in science challenge the timely adoption of evidence-based care in community settings. To bridge the gap between what is possible and what is practiced, we researched approaches...
28.
Lam V, Tran H, Banks K, Lanman R, Rinsurongkawong W, Peled N, et al.
Clin Lung Cancer
. 2018 Oct;
20(1):30-36.e3.
PMID: 30279110
Background: Major guidelines do not recommend routine molecular profiling of lung squamous-cell carcinoma (LUSC) because the prevalence of actionable alterations is thought to be low. Increased utilization of next-generation sequencing...
29.
Blumenthal G, Bunn Jr P, Chaft J, McCoach C, Perez E, Scagliotti G, et al.
J Thorac Oncol
. 2018 Oct;
13(12):1818-1831.
PMID: 30268698
This Review Article provides a multi-stakeholder view on the current status of neoadjuvant therapy in lung cancer. Given the success of oncogene-targeted therapy and immunotherapy for patients with advanced lung...
30.
Gomez D, Byers L, Nilsson M, Diao L, Wang J, Li L, et al.
Oncotarget
. 2018 Mar;
9(18):14268-14284.
PMID: 29581842
While several molecular targets have been identified for adenocarcinoma (ACA) of the lung, similar drivers with squamous cell carcinoma (SCC) are sparse. We compared signaling pathways and potential therapeutic targets...